BriaCell Therapeutics Corp. announced it will present significant clinical and preclinical data from its novel cancer immunotherapy pipeline at the upcoming American Association for Cancer Research (AACR) Annual Meeting, scheduled for April 25-30, 2025, in Chicago.
The clinical-stage biotechnology company will showcase three poster presentations highlighting its innovative immunotherapy platforms targeting advanced breast cancer, including data from its pivotal late-stage clinical trials.
Pivotal Phase 3 Trial Data in Metastatic Breast Cancer
The company's lead presentation will feature early biomarker correlates from its randomized registration trial comparing Bria-ABC to physician's choice in late-stage metastatic breast cancer (MBC). This pivotal Phase 3 study (NCT06072612) represents a significant milestone in BriaCell's development of novel cancer immunotherapies.
The late-breaking research presentation, scheduled for April 30th, will provide insights into the efficacy and safety profile of the Bria-IMT regimen combined with checkpoint inhibitors versus standard treatment options for patients with advanced metastatic breast cancer.
Metastatic breast cancer remains a significant clinical challenge with limited effective treatment options for late-stage patients. BriaCell's approach leverages the body's immune system to target cancer cells through its proprietary whole-cell immunotherapy platform.
Phase 2 Survival Outcomes for Bria-IMT Cancer Vaccine
A second poster will present survival outcomes from a randomized Phase 2 trial of Bria-IMT, described as an allogeneic whole cell cancer vaccine. This presentation, scheduled for April 28th, will provide critical data on the durability of response and overall survival metrics for this novel immunotherapeutic approach.
Bria-IMT represents a unique approach to cancer immunotherapy, utilizing whole tumor cells that have been engineered to stimulate a patient's immune system to recognize and attack similar cancer cells throughout the body.
Novel Immunotherapy Platform Development
The third presentation will showcase BriaCell's Bria-OTS+ platform, described as "a versatile therapeutic platform for inducing anti-cancer immunity." This poster, also scheduled for April 28th, highlights the company's expanding immunotherapy portfolio and ongoing innovation in cancer treatment approaches.
The Bria-OTS+ platform potentially represents the next generation of BriaCell's immunotherapy development, building on the company's experience with its lead candidates while exploring new mechanisms to enhance anti-cancer immune responses.
Advancing Cancer Immunotherapy
"These presentations at AACR represent significant progress in our clinical development programs," said William V. Williams, MD, President and CEO of BriaCell, in the announcement. "We look forward to sharing these important findings with the scientific community as we work to transform cancer care through novel immunotherapies."
Breast cancer remains one of the most common cancers worldwide, with metastatic disease presenting particular treatment challenges. Immunotherapy approaches have shown promise in various cancer types, though efficacy in breast cancer has been more limited compared to some other solid tumors.
BriaCell's approach aims to address these limitations through its proprietary platforms that potentially offer new options for patients with limited treatment alternatives. The company's focus on late-stage metastatic breast cancer addresses a significant unmet medical need, as these patients typically have exhausted standard treatment options.
Following the presentations, BriaCell will make copies of the posters available on its website for broader access to the scientific and investment communities.
The AACR Annual Meeting represents one of the premier gatherings for cancer researchers worldwide, bringing together scientists, clinicians, and industry representatives to share the latest advances in cancer research and treatment development.
BriaCell Therapeutics Corp. is listed on both Nasdaq (BCTX, BCTXW) and the Toronto Stock Exchange (BCT), reflecting its dual-market presence in the biotechnology sector.
